Vireo Growth (VREOF) Accounts Payables (2020 - 2026)
Vireo Growth (VREOF) reported Accounts Payables of $58.3 million for Q1 2026, up 801.93% on a YoY basis from $6.5 million in Q1 2025, and up 15.9% sequentially from $50.3 million in Q4 2025.
Vireo Growth (VREOF) Accounts Payables (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Accounts Payables data on file, last reported at $58.3 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 801.93% year-over-year to $58.3 million; the trailing twelve-month figure through Mar 2026 stood at $58.3 million (up 801.93% YoY), and the FY2025 full-year result was $50.3 million, up 2088.8% from the prior year.
- Accounts Payables grew to $58.3 million in Q1 2026, from $50.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $58.3 million in Q1 2026 to a low of $1.5 million in Q3 2023.
- A 5-year average of $17.6 million and a median of $14.9 million in 2025 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables plunged 91.44% in 2023 and soared 2088.8% in 2025, its largest moves.
- Tracing VREOF's Accounts Payables over 5 years: stood at $14.9 million in 2022, then sank by 48.59% to $7.7 million in 2023, then sank by 70.06% to $2.3 million in 2024, then soared by 2088.8% to $50.3 million in 2025, then increased by 15.9% to $58.3 million in 2026.
- Business Quant data shows VREOF's Accounts Payables at $58.3 million in Q1 2026, $50.3 million in Q4 2025, and $14.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 507.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 498.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1.67 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 372.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 58.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.30 Mn |
| Dec 31, 2025 | 50.30 Mn |
| Sep 30, 2025 | 14.91 Mn |
| Jun 30, 2025 | 47.45 Mn |
| Mar 31, 2025 | 6.46 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 3.76 Mn |
| Jun 30, 2024 | 9.18 Mn |
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 7.67 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Jun 30, 2023 | 27.09 Mn |
| Mar 31, 2023 | 15.60 Mn |
| Dec 31, 2022 | 14.93 Mn |
| Sep 30, 2022 | 17.24 Mn |
| Jun 30, 2022 | 2.53 Mn |
| Mar 31, 2022 | 17.69 Mn |
| Dec 31, 2021 | 14.81 Mn |
| Sep 30, 2021 | 9.53 Mn |
| Jun 30, 2021 | 1.30 Mn |